Huons Global Co. Ltd (084110) - Total Liabilities

Latest as of March 2026: ₩466.09 Billion KRW ≈ $315.86 Million USD

Based on the latest financial reports, Huons Global Co. Ltd (084110) has total liabilities worth ₩466.09 Billion KRW (≈ $315.86 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Huons Global Co. Ltd (084110) long-term investment share to see how much of total assets are deployed in long-term investments.

Huons Global Co. Ltd - Total Liabilities Trend (2010–2025)

This chart illustrates how Huons Global Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Huons Global Co. Ltd total assets.

Huons Global Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Huons Global Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
CVW Sustainable Royalties Inc.
V:CVW
Canada CA$861.47K
Better Home & Finance Holding Company
NASDAQ:BETR
USA $1.48 Billion
Premia S.A.
AT:PREMIA
Greece €457.50 Million
Dollar Industries Limited
NSE:DOLLAR
India Rs5.90 Billion
Loandepot Inc
NYSE:LDI
USA $6.36 Billion
PPX Mining Corp
V:PPX
Canada CA$66.12 Million
Phuoc Hoa Rubber JSC
VN:PHR
Vietnam ₫1.90 Trillion
Tachan Securities Co Ltd
TWO:6020
Taiwan NT$3.02 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Huons Global Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 084110 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.80 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.85 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Huons Global Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Huons Global Co. Ltd (2010–2025)

The table below shows the annual total liabilities of Huons Global Co. Ltd from 2010 to 2025.

Year Total Liabilities Change
2025-12-31 ₩468.69 Billion
≈ $317.63 Million
-47.09%
2024-12-31 ₩885.84 Billion
≈ $600.32 Million
+117.50%
2023-12-31 ₩407.29 Billion
≈ $276.01 Million
-47.70%
2022-12-31 ₩778.79 Billion
≈ $527.78 Million
+4.41%
2021-12-31 ₩745.91 Billion
≈ $505.49 Million
+39.11%
2020-12-31 ₩536.19 Billion
≈ $363.37 Million
+47.46%
2019-12-31 ₩363.63 Billion
≈ $246.42 Million
+17.05%
2018-12-31 ₩310.66 Billion
≈ $210.53 Million
+15.49%
2017-12-31 ₩269.00 Billion
≈ $182.30 Million
+13.38%
2016-12-31 ₩237.26 Billion
≈ $160.79 Million
+63.41%
2015-12-31 ₩145.19 Billion
≈ $98.39 Million
+119.53%
2014-12-31 ₩66.14 Billion
≈ $44.82 Million
-18.34%
2013-12-31 ₩80.99 Billion
≈ $54.88 Million
-12.54%
2012-12-31 ₩92.60 Billion
≈ $62.76 Million
+45.65%
2010-12-31 ₩63.58 Billion
≈ $43.09 Million
--

About Huons Global Co. Ltd

KQ:084110 Korea Pharmaceuticals
Market Cap
$163.58 Million
₩241.38 Billion KRW
Market Cap Rank
#17383 Global
#700 in Korea
Share Price
₩22250.00
Change (1 day)
+0.23%
52-Week Range
₩20600.00 - ₩75300.00
All Time High
₩75300.00
About

Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and inj… Read more